Biogen passes FDA test for Alzheimer's medicine

The FDA has approved Biogen's Alzheimer's drug, aducanumab.


Pharmaceutical company Biogen's share prices are increasing rapidly on the US stock exchange after the US health authority, the Food and Drug Administration (FDA), approved its Alzheimer's medication on Monday.

Biogen entered the stock exchange before the approval, and in the first minutes of trading after it was obtained, the share price rose by 58 percent to USD 452.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs